

**The Mechanisms and Role of HIF-PHs in Patients with CKD and Anemia:
Advances in the Therapeutic Landscape
TwitterChat #1 References**

Statement 1:

Stauffer ME, Fan T. *PLOS One*. 2014;9(1):e84943.
Sato Y, et al. *Clin Exp Nephrol*. 2018;22(2):388-394.
Covic A, et al. *Adv Ther*. 2017;34:1662-1672.
Thorp ML, et al. *Nephrology*. 2009;14(2):240-246.

Question 1:

Fishbane S, Spinowitz B. *Am J Kidney Dis*. 2018;71(3):423-435.

Question 2:

<https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-modified-dosing-recommendations-improve-safe-use-erythropoiesis#table>

Stancu S, et al. *Clin J Am Soc Nephrol*. 2010;5(3):409-416.

Question 3:

Locatelli F, et al. *Am J Nephrol*. 2017;45(3):187-199.
Ford BA, et al. *Kidney Int*. 2010;78(8):769-773.
Coyne DW. *Kidney Int*. 2011;80(3):240-244.

Question 4:

Vita A, et al. *Cells*. 2020;9(4):992.